162 related articles for article (PubMed ID: 24262935)
21. PML/RARalpha fusion protein mediates the unique sensitivity to arsenic cytotoxicity in acute promyelocytic leukemia cells: Mechanisms involve the impairment of cAMP signaling and the aberrant regulation of NADPH oxidase.
Li L; Wang J; Ye RD; Shi G; Jin H; Tang X; Yi J
J Cell Physiol; 2008 Nov; 217(2):486-93. PubMed ID: 18636556
[TBL] [Abstract][Full Text] [Related]
22. [Effect of arsenic trioxide and 5-aza-2'-deoxycytidine on SHP-1, JAK3, TYK2 gene expression in K562 cells].
Zhang XK; Luo JM; Sun J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Apr; 22(2):323-8. PubMed ID: 24762999
[TBL] [Abstract][Full Text] [Related]
23. Arsenic trioxide mediates intrinsic and extrinsic pathways of apoptosis and cell cycle arrest in acute megakaryocytic leukemia.
Lam HK; Li K; Chik KW; Yang M; Liu VC; Li CK; Fok TF; Ng PC; Shing MM; Chuen CK; Yuen PM
Int J Oncol; 2005 Aug; 27(2):537-45. PubMed ID: 16010437
[TBL] [Abstract][Full Text] [Related]
24. Acute promyelocytic leukemia: a paradigm for differentiation therapy.
Grimwade D; Mistry AR; Solomon E; Guidez F
Cancer Treat Res; 2010; 145():219-35. PubMed ID: 20306254
[TBL] [Abstract][Full Text] [Related]
25. ASK1 is activated by arsenic trioxide in leukemic cells through accumulation of reactive oxygen species and may play a negative role in induction of apoptosis.
Yan W; Arai A; Aoki M; Ichijo H; Miura O
Biochem Biophys Res Commun; 2007 Apr; 355(4):1038-44. PubMed ID: 17331470
[TBL] [Abstract][Full Text] [Related]
26. Curcumin stimulates reactive oxygen species production and potentiates apoptosis induction by the antitumor drugs arsenic trioxide and lonidamine in human myeloid leukemia cell lines.
Sánchez Y; Simón GP; Calviño E; de Blas E; Aller P
J Pharmacol Exp Ther; 2010 Oct; 335(1):114-23. PubMed ID: 20605902
[TBL] [Abstract][Full Text] [Related]
27. Promyelocytic leukemia protein induces arsenic trioxide resistance through regulation of aldehyde dehydrogenase 3 family member A1 in hepatocellular carcinoma.
Zhang X; Yang XR; Sun C; Hu B; Sun YF; Huang XW; Wang Z; He YF; Zeng HY; Qiu SJ; Cao Y; Fan J; Zhou J
Cancer Lett; 2015 Sep; 366(1):112-22. PubMed ID: 26118777
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
29. Growth-inhibiting effects of arsenic trioxide plus epigenetic therapeutic agents on leukemia cell lines.
Peng CY; Jiang J; Zheng HT; Liu XS
Leuk Lymphoma; 2010 Feb; 51(2):297-303. PubMed ID: 20038232
[TBL] [Abstract][Full Text] [Related]
30. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent.
Amadori S; Fenaux P; Ludwig H; O'dwyer M; Sanz M
Curr Med Res Opin; 2005 Mar; 21(3):403-11. PubMed ID: 15811209
[TBL] [Abstract][Full Text] [Related]
31. Potentiation of arsenic trioxide-induced apoptosis by 8-bromo-7-methoxychrysin in human leukemia cells involves depletion of intracellular reduced glutathione.
Xiao G; Tang X; Yao C; Wang C
Acta Biochim Biophys Sin (Shanghai); 2011 Sep; 43(9):712-21. PubMed ID: 21785114
[TBL] [Abstract][Full Text] [Related]
32. Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide.
Gao SM; Chen C; Wu J; Tan Y; Yu K; Xing CY; Ye A; Yin L; Jiang L
Biochem Biophys Res Commun; 2010 Dec; 403(2):203-8. PubMed ID: 21056550
[TBL] [Abstract][Full Text] [Related]
33. Role of the p38 mitogen-activated protein kinase pathway in the generation of arsenic trioxide-dependent cellular responses.
Giafis N; Katsoulidis E; Sassano A; Tallman MS; Higgins LS; Nebreda AR; Davis RJ; Platanias LC
Cancer Res; 2006 Jul; 66(13):6763-71. PubMed ID: 16818652
[TBL] [Abstract][Full Text] [Related]
34. Increased apoptotic efficacy of lonidamine plus arsenic trioxide combination in human leukemia cells. Reactive oxygen species generation and defensive protein kinase (MEK/ERK, Akt/mTOR) modulation.
Calviño E; Estañ MC; Simón GP; Sancho P; Boyano-Adánez Mdel C; de Blas E; Bréard J; Aller P
Biochem Pharmacol; 2011 Dec; 82(11):1619-29. PubMed ID: 21889928
[TBL] [Abstract][Full Text] [Related]
35. Investigating critical genes and gene interaction networks that mediate cyclophosphamide sensitivity in chronic myelogenous leukemia.
He X; Deng Y; Yue W
Mol Med Rep; 2017 Jul; 16(1):523-532. PubMed ID: 28560425
[TBL] [Abstract][Full Text] [Related]
36. Low-dose 1,25-dihydroxyvitamin D(3) combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis.
Bae JY; Kim JW; Kim I
Oncol Rep; 2013 Jul; 30(1):485-91. PubMed ID: 23660868
[TBL] [Abstract][Full Text] [Related]
37. Arsenic trioxide inhibits the Hedgehog pathway which is aberrantly activated in acute promyelocytic leukemia.
Yang D; Cao F; Ye X; Zhao H; Liu X; Li Y; Shi C; Wang H; Zhou J
Acta Haematol; 2013; 130(4):260-7. PubMed ID: 23867347
[TBL] [Abstract][Full Text] [Related]
38. EZH2 mediates ATO-induced apoptosis in acute myeloid leukemia cell lines through the Wnt signaling pathway.
Zhang H; Gu H; Li L; Ren Y; Zhang L
Tumour Biol; 2016 May; 37(5):5919-23. PubMed ID: 26592252
[TBL] [Abstract][Full Text] [Related]
39. Targeting Hsp90 by 17-AAG in leukemia cells: mechanisms for synergistic and antagonistic drug combinations with arsenic trioxide and Ara-C.
Pelicano H; Carew JS; McQueen TJ; Andreeff M; Plunkett W; Keating MJ; Huang P
Leukemia; 2006 Apr; 20(4):610-9. PubMed ID: 16482209
[TBL] [Abstract][Full Text] [Related]
40. Targeted degradation of the AML1/MDS1/EVI1 oncoprotein by arsenic trioxide.
Shackelford D; Kenific C; Blusztajn A; Waxman S; Ren R
Cancer Res; 2006 Dec; 66(23):11360-9. PubMed ID: 17145882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
